Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

164.84 0.76 −0.46%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
−139×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 160.21 0.00 0.00 253.15
Piotroski F-Score
3 4 3 1 5 2 2 4 5 7
P/S ratio
12.73 20.63 11.86 7.36 7.02 14.89 8.59 10.94 5.85 9.71
Altman Z-Score
15.20 22.21 4.23 2.44 2.85 5.83 8.48 36.08 19.33 39.51
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 232.05 47.07 184.10
Altman Z″-Score (non-manufacturers)
0.74 3.06 0.26 1.55 2.63 2.98 5.35 6.49 6.23 7.79
Beneish M-Score
(2.96) (2.26) (2.79) (2.73) (2.90) (3.28) 2.81 (2.64) (3.28) (2.05)
P/Operating CF
943.64 15,601.75 (350.04) (503.35) (443.57) 315.81 (485.50) 115.82 74.71 338.72
P/B ratio
9.84 10.31 8.08 3.93 3.51 5.02 3.02 11.41 6.74 9.47
Price to Tangible BV
14.43 18.09 33.13 13.35 10.96 13.75 9.06 11.44 6.89 10.03
EV/Sales
12.86 20.71 12.93 8.35 7.76 14.21 8.11 10.19 5.12 8.90
EV/EBITDA
0.00 0.00 0.00 0.00 577.48 0.00 0.00 0.00 253.28 111.01
EV/Operating CF
(441.27) (129.49) (70.47) (71.40) 92.32 (139.01) (5,206.45) 97.92 31.27 82.73
EV/FCF
(167.07) (117.49) (52.18) (37.38) (98.86) (106.79) (377.22) 216.06 41.25 168.84
Quick Ratio
3.82 5.05 4.53 5.37 7.06 8.86 3.68 5.24 5.06 6.50
Current Ratio
4.69 5.99 5.34 6.13 7.67 9.45 4.56 5.81 5.58 7.09
Net Debt/EBITDA
1.31 2.91 (0.64) (0.02) (15.53) 2.67 3.14 19.98 (36.95) (10.45)
Debt/Assets
7.62% 7.13% 37.57% 35.27% 33.60% 24.87% 7.14% 0.00% 0.00% 0.00%
Debt/Equity
0.10 0.09 0.77 0.67 0.60 0.37 0.09 0.00 0.00 0.00
Asset Turnover
0.54 0.40 0.32 0.28 0.29 0.25 0.46 0.97 1.06 0.91
Operating CF/Net income
0.08 0.42 0.43 0.33 (0.50) 0.19 (0.02) (1.46) (283.60) 2.72
Capex/Depreciation
(0.62) (0.17) (0.54) (0.79) (1.30) (0.11) (0.35) (1.73) (1.15) (1.27)
Interest Coverage
(43.06) (12.19) (9.44) (6.00) (2.46) (8.75) (19.61) (5.77) (1.66) 4.77
ROE
(26.38%) (23.83%) (27.16%) (17.76%) (7.91%) (17.95%) 3.64% (8.30%) (0.07%) 4.26%
ROA
(20.09%) (15.29%) (13.86%) (9.67%) (4.83%) (13.20%) 3.01% (6.95%) (0.06%) 3.60%
ROIC
(28.00%) (14.78%) (15.48%) (9.69%) (3.91%) (15.05%) (5.64%) (24.35%) (7.43%) 12.37%
Return on Tangible Assets
(38.54%) (30.98%) (31.71%) (21.29%) (10.09%) (27.12%) 6.79% (7.83%) (0.07%) 4.09%
Average Days of Receivables
78.12 57.82 46.22 46.55 41.51 58.51 59.17 37.60 38.17 45.64
Research and Development Expense of Revenue
29.68% 39.29% 45.68% 47.12% 34.35% 37.96% 28.82% 27.40% 24.43% 25.55%
Selling, General and Administrative Expense of Revenue
65.38% 68.10% 71.20% 68.20% 60.97% 76.19% 74.53% 65.94% 60.44% 56.61%
Intangible Assets out of Total Assets
0.23 0.34 0.37 0.37 0.38 0.42 0.55 0.00 0.02 0.05
Share Based Compensation of Revenue
12.46% 13.09% 13.83% 13.63% 10.25% 20.66% 15.36% 14.18% 11.05% 7.68%
Graham Net Nets
0.04 0.03 (0.02) (0.01) 0.01 0.04 0.06 0.07 0.13 0.09
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 11.74 0.00 0.00 3.27
Earnings Yield
(2.89%) (1.91%) (3.61%) (4.76%) (2.43%) (3.63%) 0.62% (0.66%) 0.00% 0.40%
Free Cash Flow Yield
(0.60%) (0.85%) (2.09%) (3.04%) (1.12%) (0.89%) (0.25%) 0.43% 2.12% 0.54%
Revenue per Share
8.87 7.27 6.50 5.96 6.33 5.06 6.34 5.13 4.63 3.47
Operating CF per Share
(0.26) (1.16) (1.19) (0.70) 0.53 (0.52) (0.01) 0.53 0.76 0.37
Capex per Share
(0.42) (0.12) (0.42) (0.63) (1.03) (0.16) (0.13) (0.29) (0.18) (0.19)
Free Cash Flow per Share
(0.68) (1.28) (1.61) (1.33) (0.50) (0.67) (0.14) 0.24 0.58 0.18
Cash per Share
4.87 6.05 6.10 7.43 8.92 9.09 4.66 3.98 3.46 2.91
Shareholders Equity per Share
11.47 14.54 9.53 11.17 12.65 15.00 18.02 4.92 4.02 3.56
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
11.47 14.54 9.53 11.17 12.65 15.00 18.02 4.92 4.02 3.56
Free Cash Flow
(39.06) (67.58) (78.01) (63.20) (23.07) (29.92) (5.09) 8.55 19.78 6.03
Working Capital
373.71 374.67 321.45 371.50 422.77 419.74 205.18 146.20 122.67 103.09
Capital Expenditures
(24.27) (6.26) (20.25) (30.11) (47.78) (6.93) (4.72) (10.31) (6.31) (6.28)
Net Current Asset Value
237.65 241.97 (83.19) (28.52) 23.58 131.39 117.75 143.46 121.83 102.93
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 240.11
Capex to Sales
0.05 0.02 0.06 0.11 0.16 0.03 0.02 0.06 0.04 0.05
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 261.81
Other line items
Depreciation/Fixed assets
0.35 0.37 0.36 0.40 0.53 2.74 0.61 0.31 0.47 0.65
Cash ROIC
(3.89%) (5.85%) (7.02%) (5.11%) (1.70%) (2.26%) (0.56%) 2.72% 7.69% 2.83%
Accounts Receivable Turnover
5.99 7.62 8.29 8.14 8.46 6.04 8.30 10.26 10.29 10.47
Accounts Payable Turnover
5.94 7.11 5.43 6.35 11.39 18.07 6.40 4.00 4.57 4.91
Inventory Turnover
1.84 1.89 1.89 2.27 3.43 3.14 1.38 2.05 2.33 2.96
Average Days of Payables
80.38 50.57 64.91 76.21 40.17 17.39 54.68 91.50 108.27 66.94
Days of Inventory on Hand
207.50 223.90 202.78 200.23 126.06 62.91 402.74 193.34 194.59 154.42
Average Receivables
84.68 50.30 37.96 34.76 34.75 37.24 28.55 17.66 15.48 10.93
Average Payables
18.83 13.23 13.92 10.87 5.85 5.08 6.03 6.27 4.61 3.30
Average Inventory
60.62 49.83 39.91 30.43 19.41 29.19 27.93 12.25 9.03 5.47
Average Assets
934.12 957.59 971.40 1,026.04 1,027.60 911.95 512.69 186.40 150.10 125.52
Average Common Equity
711.54 614.35 495.89 558.58 627.30 670.36 423.57 156.03 127.74 106.23

Fold the line items

Columns are period end dates